Bajaj Housing Finance Limited files DRHP with SEBI for an IPO

Bajaj Housing Finance Limited (BHFL), part of the Bajaj Group (with Bajaj Finance Limited and Bajaj Finserv Limited as promoters), has filed Draft Red Herring Prospectus (DRHP) with SEBI for an Initial Public Offering (IPO). BHFL is a non-deposit taking Housing Finance Company (“HFC”), registered with the National Housing Bank (“NHB”) since September 24, 2015, and engaged in mortgage lending since Fiscal 2018.

The Public Offer aggregating up to ₹7,000 crore comprises a fresh issue of equity shares of up to ₹4,000 crore and an offer for sale (OFS) of up to ₹3,000 crore by the “Selling Shareholder” (The “Offer for Sale”) with face value of ₹10 each equity share by Bajaj Finance Limited (The “Promoter Selling Shareholder”). 

The Public Offer Includes a reservation of Equity Shares for subscription by Eligible Employees (“Employee Reservation Portion”) and a reservation Equity Shares of Face Value of ₹10 each for subscription by Eligible Shareholders of promoters (“Shareholders Reservation Portion”) including individuals and HUFs who are public equity shareholders of the Promoters.

BHFL proposes to use the net proceeds for augmenting the company’s capital base to meet future business requirements of the company towards onward lending.

This Offer is being made in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. Not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”, and such portion, the “QIB Portion”) provided that the Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations (“Anchor Investor Portion”), of which at least one-third shall be available for allocation to domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. Further, not less than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders. Not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders (“RIBs”) in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective bank accounts (including UPI ID for UPI Bidders using UPI Mechanism) (as defined hereinafter) in which the Bid amount will be blocked by the SCSBs or the Sponsor Banks, as applicable, to participate in the Offer.

The Company, in consultation with the BRLMs, may consider an issue of specified securities, as may be permitted under applicable law, at its discretion, prior to filing of the Red Herring Prospectus with the RoC (“Pre-IPO Placement”).

The Equity Shares that will be offered through the Red Herring Prospectus are proposed to be listed on the Stock Exchanges, being BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”, and together with BSE, the “Stock Exchanges”).

Kotak Mahindra Capital Company Limited, BofA Securities India Limited, Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, SBI Capital Markets Limited, JM Financial Limited, and IIFL Securities Limited are the Book Running Lead Managers to the issue.

 

Comments

Post a Comment

Popular posts from this blog

First DPL match was won by US Consulate Staff Team

Image
  ICWO - Indian Community Welfare Organisation  organized the First DPL- Diplomat Cricket Tournament for Embassy, Consulate & High Commission Staff on 10 th   August 2024 at Soka Ikeda College of Arts and Science for Women, Sethu Bhaskara Nagar, Madhanangkuppam, Kolathur, Chennai. T he event aims to create high level Awareness to STOP Child Abuse, Child Trafficking, Child Marriage & Child Labour in Tamilnadu and mobilize funds for intervention to address the same. A.J.Hariharan, Secretary – ICWO thanked both the US Consulate and Malaysian Consulate for their support and participation in the diplomate cricket tournament as to create an awareness about the Child Marriage, Child Trafficking & Child Labour and Child Abuse in Tamilnadu. The tournament has created huge interest among the players and the consul officials. We, ICWO have plan to organize similar event on 3 rd  May 2025. This time for men and women doubles badminton tournament. We emphasis there is...
Read more

TATA AIG Strengthens Tamil Nadu Health Insurance Portfolio with New Riders amid Strong Growth

Image
Chennai, 12 November 2024: TATA AIG General Insurance, a leading general insurance provider in India, is strengthening its health insurance offerings in Tamil Nadu with five specialised riders: Mental Wellbeing, Empower Her, OPD Care, CanCare, and Flexi Shield. These riders are specifically designed to address the unique and diverse healthcare needs of the state’s residents, providing enhanced protection in areas such as mental health, women’s health, cancer treatment, and routine medical costs. TATA AIG has established a robust presence across 31 districts in Tamil Nadu, with key branches in Chennai, Coimbatore, Madurai, Tiruchirapalli, Tirunelveli, and Salem. The company’s expansive network includes over 1000 hospitals, ensuring seamless access to cashless treatment for its customers across both urban and rural regions. With a well-established network of agents and digital platforms, the company is bringing quality health insurance solutions to every corner of the state. This pe...
Read more

Apollo Cancer Centers now introduces Made in India, CAR T Cell Program

Image
First Private Hospital in India to Successfully Complete CAR T Cell Therapy.  In a ground-breaking development, Apollo Cancer Centres (ACCs) has emerged as the first private hospital group in India to have a successfully complete CAR-T cell program and to further augment it, the group will now provide access to Made in India CAR-T cell therapy, beginning with NexCAR19 (Actalycabtagene autoleucel), for the treatment of B-cell lymphomas and B-acute lymphoblastic leukaemia in patients aged 15 years and above.   Marking a historic moment in the country's medical landscape , Dr. T Raja, Director of Medical Oncology at ACC, Chennai, spearheaded the development of this revolutionary clinical program, and has successfully treated six patients till date.   CAR-T cell therapies, often known as living drugs involve the extraction of a patients T-cells (a type of white blood cells whose function is to fight cancer cells) through a process known as Apheresis. These T-cells are t...
Read more